MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s13555-026-01962-0

Медицинская библиотека · Dermatology and therapy · 2026

Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic Dermatitis.

Gold Linda Stein, Wollenberg Andreas, Lio Peter, Carrascosa Jose Manuel, Del Rosso James, Igawa Ken, Hong H Chih-Ho, Merola Joseph, Kircik Leon, Gallo Gaia, Ding Yuxin, Yang Chao, Wolf Eric, Agell Helena, Vestergaard Christian

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Lebrikizumab provides lasting improvements in skin clearance and itch relief in patients with moderate-to-severe atopic dermatitis (AD). This analysis assessed long-term stability, depth of response, and flare incidence through 3 years in week 16 responders from ADvocate1 and ADvocate2 who continued maintenance lebrikizumab regimen (every 4 weeks [Q4W] or every 2 weeks [Q2W]) in the ADjoin extension study.

METHODS

Responders achieved either an Investigator's Global Assessment (IGA) score of 0 or 1 with ≥ 2-point improvement or ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16, without rescue medication use. Long-term deep response was defined by skin and itch endpoints (3 years: IGA 0, ≥ 90% improvement from baseline in EASI [EASI 90], 100% improvement from baseline in EASI [EASI 100], absolute EASI score of ≤ 1 [EASI ≤ 1], Patient-Oriented Eczema Measure [POEM] [0, 1], POEM itch [0, 1]; 2 years: Pruritus Numeric Rating Scale [0, 1]). Stability was defined as maintaining outcomes at ≥ 80% of attended visits between week 16 and week 152. Flares were evaluated via three definitions: any rescue therapy use, high-potency topical corticosteroids or systemic intervention, or adverse events due to AD exacerbation.

RESULTS

After 152 weeks of continuous treatment, 88.6% (Q4W) and 80.0% (Q2W) of week 16 responders maintained EASI 90, while 64.3% (Q4W) and 68.8% (Q2W) maintained EASI 100. Most patients achieving EASI 90 or EASI 100 at week 16 maintained stable responses through week 152 (Q4W: 77.8% and 57.9%; Q2W: 81.1% and 63.6%, respectively). Among stable EASI 75 responders (Q4W), 72.8% did not experience any flare through week 152, with an incidence rate of 0.19 flares per patient-year (~1 flare every 5 patient-years). Improvements in itch outcomes were sustained over time and followed patterns similar to those observed for skin responses.

CONCLUSIONS

Continuous lebrikizumab treatment through 3 years provided stable disease control in skin and itch symptoms, with infrequent flares experienced by week 16 responders with moderate-to-severe AD.

TRIAL REGISTRATION: ClinicalTrials.gov NCT04146363, NCT04178967, and NCT04392154.

Для цитирования: Gold Linda Stein, Wollenberg Andreas, Lio Peter, Carrascosa Jose Manuel, Del Rosso James, Igawa Ken, Hong H Chih-Ho, Merola Joseph, Kircik Leon, Gallo Gaia, Ding Yuxin, Yang Chao, Wolf Eric, Agell Helena, Vestergaard Christian. Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic Dermatitis.. Dermatology and therapy. 2026. DOI: 10.1007/s13555-026-01962-0.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.